Sign In
Buy MBRX
$0.400
-0.620 (-60.78%)
At Close: Jul 31, 2026
Moleculin Announces FDA Permission to Begin Clinical Study of Annamycin for Sarcoma Lung Metastases
07:30am, Thursday, 17'th Dec 2020
HOUSTON, Dec. 17, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting h
HOUSTON, Dec. 3, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hi
MBRX Stock: Why Moleculin Biotech Is Soaring 21% Today
12:47pm, Tuesday, 01'st Dec 2020
Moleculin Biotech (MBRX) is seeing shares of MBRX stock soar higher on Tuesday after announcing news concerning one of its drug candidates. The post MBRX Stock: Why Moleculin Biotech Is Soaring 21% To
Moleculin Announces FDA Approves 3 Rare Pediatric Disease Designations for WP1066
07:30am, Tuesday, 01'st Dec 2020
HOUSTON, Dec. 1, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hi
Moleculin Announces New Data Demonstrating Synergistic Antitumor Activity of Annamycin Combination with Ara-C in AML
07:30am, Thursday, 19'th Nov 2020
HOUSTON, Nov. 19, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting h
Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended September 30, 2020
07:30am, Friday, 13'th Nov 2020
HOUSTON, Nov. 13, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting h
Moleculin Announces Additional Collaboration on Drug Candidate Targeting COVID-19
07:30am, Thursday, 29'th Oct 2020
HOUSTON, Oct. 29, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeti
Moleculin to Participate in Panel at ROTH Capital's "COVID-19 Therapeutics in Development" Healthcare Event
07:30am, Tuesday, 27'th Oct 2020
HOUSTON, Oct. 27, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting s
Moleculin Biotech (MBRX) Investor Presentation - Slideshow
07:03pm, Wednesday, 02'nd Sep 2020
The following slide deck was published by Moleculin Biotech, Inc. in conjunction with this event..
Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended June 30, 2020
11:30am, Wednesday, 12'th Aug 2020
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, ann
Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
01:13pm, Tuesday, 11'th Aug 2020
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Moleculin Biotech (MBRX) Gets a Buy Rating from Maxim Group - Markets
03:30pm, Wednesday, 22'nd Jul 2020
In a report released yesterday, Jason McCarthy from Maxim Group assigned a Buy rating to Moleculin Biotech (MBRX – Research
Dow, S&P close higher as Covid-battered stocks surge, but off session’s best levels as tech sector sinks
09:24pm, Tuesday, 21'st Jul 2020
U.S. stock-indexes finish mostly higher Tuesday, but off the session’s best levels, as investors snap up beaten-down energy and financial stocks amid a slate...
Coronavirus update: U.S. case tally climbs above 3.8 million; President Trump appears to have changed his view on face masks
08:11pm, Tuesday, 21'st Jul 2020
The number of confirmed cases of the coronavirus illness COVID-19 in the U.S. rose above 3.8 million on Tuesday, and President Donald Trump appeared to...
Moleculin Pops 33% On Anti-Viral Activity For Potential Covid-19 Treatment
01:59pm, Tuesday, 21'st Jul 2020
Moleculin Biotech (MBRX) on Tuesday announced that a second round of independent laboratory testing has confirmed the antiviral activity of its drug candidate WP1122 as a potential treatment against c
